Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

– PEGylated enzyme replacement therapy designed to provide a long half-life – PARMA, Italy, BOSTON and CARMIEL, Israel, May 5, 2023 /PRNewswire/ — Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people…